Vivalis Acquires New Platform for Generating Human MAbs

February 11, 2010

Vivalis (Nantes, France) has acquired Humalys SAS, a private French biotech research and development company based in Lyon, specialized in the generation of human MAbs.

Vivalis (Nantes, France) has acquired Humalys SAS, a private French biotech research and development company based in Lyon, specialized in the generation of human monoclonal antibodies (MAbs). Humalys has developed a proprietary technology platform, Humalex, which can identify and generate fully human MAbs against a therapeutic target or diagnostic objective.

The Humalex technology can isolate fully human MAbs from human B-lymphocytes isolated directly from selected donors for the targeted pathology. This platform has demonstrated its potential for infectious diseases with the identification of human MAbs directed against viral and bacterial pathologies, including nosocomial infections, and has isolated human MAbs directed against the natural anti-immune repertory.

By leveraging their resources, the new Vivalis—Humalys venture will accelerate the industrialization and commercialization of the Humalex platform and extend its applications to other areas of therapeutic interest (i.e., cancer, inflammatory, and degenerative diseases).